期刊文献+

氟伐他汀对肾小球系膜细胞产生细胞外基质的影响 被引量:2

Effect of fluvastatin on production of extracellular matrix in glomerular mesangial cell
下载PDF
导出
摘要 [目的]观察不同葡萄糖浓度环境、氟伐他汀对人系膜细胞表达FN、IV型胶原作用。[方法]培养人肾小球系膜细胞,分为正常葡萄糖组、高葡萄糖组及加氟伐他汀组,培养244、8 h收集细胞上清液,用酶联免疫法检测FN、IV型胶原。[结果]在高糖组24、48 h FN分别是(1.552±0.546)和(2.547 0±0.968)ng/mL,明显高于正常糖组244、8 h,FN:(0.777±0.076)和(1.180±0.091)ng/mL(P<0.01);在高糖组244、8 h IV型胶原分别是(64.577±5.543)和(80.140±6.605)ng/mL,明显高于正常糖组24、48 h IV型胶原:(42.468±5.615)和(46.368±5.714)ng/mL(P<0.01)。氟伐他汀可减少高糖浓度下细胞上清液中FN、Ⅳ型胶原的表达水平。在高糖组与氟伐他汀(1μmol/L,10μmol/L)作用24、48 h FN和IV型胶原分别是(0.955±0.102)(、0.858±0.081)ng/mL,(0.652±0.078)(、0.822±0.257)ng/mL(P<0.01)、(34.908±4.283)、(32.163±2.220)、(28.260±4.287)(、23.233±7.284)ng/mL(P<0.01)。[结论]氟伐他汀可抑制高糖刺激的系膜细胞表达FN、Ⅳ型胶原。 [ Objective] To observe the effect of glucose concentration, fluvastatin on human mesangial cells to produce FN and collagen Ⅳ. [Methods] Human mesangial cells were cultured . Then all cultured cells were divided into normal glucose group,high glucose group and experimental groups . Human mesangial cells were incubated with different glucose (5 or 25 mmol/L) with or without different concentrations of fluvastatin for 48 hours. Type Ⅳcollagen and fibronectin (FN) levels were assessed by ELISA. [Results] Human glomerular mesangial cells in different glucose expressed FN and type Ⅳ collagen. Fluvastatin decreased the level of cell culture supernatant of FN and type Ⅳ collagen in high glucose. The levels of FN in 25 mmol/L glucose at 24 or 48 hours being ( 1.552 ±0.546) and (2.547 ±0.968) ng/mL were significantly higher than those in 5.0 mmol/L glucose being (0.777 ± 0.076) and ( 1. 180 ± 0.091) ng/mL ( P 〈 0.01). The levels type Ⅳ collagen of in 25 mmol//L glucose at 24 or 48 hours being (64. 577 ± 5.543) ng/mL and (80. 140 ± 6.605) ng/mL were significantly higher than those in 5.0 mmol/L glucose being (42.468 ± 5.616) and (46. 368 ± 5.714) ng/mL ( P 〈 0.01). The levels of FN and type Ⅳ collagen in 25 mmol/L glucose group at 24 or 48 hours were (0.955 ± 0. 102) or (0. 858 ± 0. 081 ) ng/mL, (0. 652 ± 0. 078) or (0. 822 ± 0. 257) ( P 〈 0.01 ) and (34. 908 ± 4. 283) or (32. 163 ±2. 220) ng/mL, (28.260 ± 4.287) or (23.233 ± 7.284) ( P 〈 0.01) respectively. [Conclusion] Fhvastatin decreased expression of FN and type Ⅳ collagen in cultured mesangial cell by high glucose stimulation.
作者 尹永红 吕申
出处 《大连医科大学学报》 CAS 2006年第4期293-295,共3页 Journal of Dalian Medical University
关键词 氟伐他汀 系膜细胞 基质 fluvastatin mesangial cell matrix
  • 相关文献

参考文献7

  • 1Hostetler TH.Prevention of end-stage renal disease due to type 2 diabetes[J].N Engl J Med,2001,345:910-911.
  • 2Rossert J,Terraz-Durasnel C,Bridean G.Growth factors,cytokines,and renal fibrosis during the course of diabetic nephropathy[J].Diabetes Metab,2000,26(4):16-24.
  • 3谌贻璞,高进,邢宝才,付玲,谌霞,邹万忠,王书和,王海燕.肾小球系膜细胞培养[J].北京医科大学学报,1989,21(4):335-336. 被引量:131
  • 4于力方,陈香美.正常人肾小球系膜细胞培养的研究[J].中华肾脏病杂志,1990,6(2):70-74. 被引量:64
  • 5文晖,林善锬.氟伐他汀对糖尿病大鼠肾脏转化生长因子β_1表达的影响[J].中华肾脏病杂志,1999,15(2):86-90. 被引量:45
  • 6Han DC,Kim JK,Cha MK,et al.Effect of HMG CoA reductase inhibition on TGF-β1 mRNA expression in diabetic rat glomeruli[J].Kidney Int,1995,48:61-65.
  • 7Yokota J,Utsumomiya KY.Mechnism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy[J].Kidney Int,1999,71:S178-181.

二级参考文献3

  • 1谌贻璞,中华医学会肾小球疾病学术会议论文摘要汇编,1987年
  • 2谌贻璞,中华医学会全国肾小球疾病学术会议文汇编,1987年
  • 3Han D C,Kidney Int,1993年,44卷,1181页

共引文献223

同被引文献22

  • 1汪燕舞,熊永炎,陈智龙,李莉.辛伐他汀对肾性高血压心肌纤维化及结缔组织生长因子的影响[J].中国临床药理学与治疗学,2004,9(10):1101-1104. 被引量:5
  • 2奚吉成,吴清玉,陈连凤.辛伐他汀对大鼠肺成纤维细胞功能及其抑制通路的影响(英文)[J].中国临床康复,2005,9(19):200-202. 被引量:2
  • 3Bataller R,Brenner D A.Liver fibrosis[J].Clin Invest,2005,115(2):209-218.
  • 4Xu L,Hoi A.Y,Albanis E,et al.Human hepatic stellate cell lines,LX-1and LX-2:new tools for analysis of hepatic fibrosis[J].Gut,2005,54(1):142-51.
  • 5Nakamura T,Akiyoshi H,Saito I,et al.Adenovirus-mediated gene expression in the septal cells of cirrhotic rat livers[J].J Hepatal,1999,30(1):101-106.
  • 6Le Bousse-Kerdilès M C,Martyré M C,Samson M.Cellular and molecular mechanisms underlying bone marrow and liver fibrosis:A review[J].Eur Cytokine Netw,2008,19(2):69-80.
  • 7Gressner O A,Rizk M S,Kovalenko E,et al.Changing the pathogenetic roadmap of liver fibrosis? Where.did it start; where will it go?[J].J Gastroenterol Hepatol,2008,23(7):1024-1035.
  • 8Albanis E,Friedman S L.Hepatic fibrosis.Pathogenesis and principles of therapy[J].Clin Liver Dis,2001,5(2):315-334.
  • 9Lamireau T,Desmouliere A,Bioulac-Sage P,et al.Mechanisms of hepatc fibrogenesis[J].Arch Pediatr,2002,9(4):392-405.
  • 10Wynn T A.Cellular and molecular mechanisms of fibrosis[J].J Pathol,2008,214(2):199-210.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部